Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Shanghai R&D Center To Focus On Diseases Prevalent In China

This article was originally published in PharmAsia News

Executive Summary

Novartis will break ground in July 2007 on an integrated biomedical R&D center in Shanghai's Zhangjiang Hi-Tech park as part of a commitment to conduct research in China, the Swiss company announced Nov. 6. Novartis will initially invest $96 mil. to create the Shanghai site

You may also be interested in...



Novartis Lines Up $1 Billion For China R&D

Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space

Novartis Lines Up $1 Billion For China R&D

Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space

Novartis Lines Up $1 Billion For China R&D

In-country research staff will increase over six-fold to approximately 1,000.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel